BPS Assessment Ltd​

BPS Assessment Limited (BPSA) remains a key element of the income diversification strategy and in 2023 sales grew by 16% on the 2022 outcome. This steady growth highlights that BPSA has developed a suite of online learning resources that help clinical professionals teach and learn safe and effective prescribing and these are being embedded into long-term teaching plans. This is further supported by the high (>90%) renewal rates of customers. The outcome of the independent review of the Prescribing Safety Assessment (PSA) offers further opportunities to embed BPSA products on a global stage, as this review provided recent evidence of the effectiveness of the UK PSA and therefore the blueprint on which BPSA products are based.  


Next: Our environmental, social and governance goals​
Previous: Our publishing portfolio​
Go back to Annual Review 2023